ed from page 560 of the application) CDC will utilize additional opportunities to recruit minority scientists utilizing programs such as the NIH Research Supplements for Underrepresented Minorities Program and the NIH Research Development Program for Minority Faculty. Candidates will be selected on the basis of their training, publication record, and letters of recommendation as well as a personal interview. Specific emphasis will be placed on recruiting women and minorities as described. Dr. Hamilton, as co-chair of the CDC, will have responsibility for monitoring the progress of awardees. Dr. Hamilton has had extensive experience in training scientists for careers in ovarian cancer research. At FCCC, he has supervised graduate students, postdoctoral fellows, research associates, and visiting scientists. Prior to coming to FCCC, Dr. Hamilton supervised medical oncology fellows and visiting scientists at the NCI. He has more than 10 trainees pursuing academic research careers throughout the world. The most recent is Steve Johnson, Ph.D., who joined the Department of Pharmacology at the University of Pennsylvania in 1998. Each awardee will have a specific mentor who is a peer-reviewed funded investigator in the Ovarian SPORE grant. The mentor will meet regularly with the awardee to provide guidance and review the status of the research project. The mentor will also ensure that the awardee is protected from clinical and administrative responsibilities. Dr. Hamilton will meet with the awardees and mentors on a quarterly basis to review scientific progress as well. The CDC will also be responsible for evaluating the progress of the Career Development awardees. This will be in the form of a yearly written report from the awardee as well as an evaluation from the mentor and from Dr. Hamilton describing the awardee's progress towards becoming an independent researcher in ovarian cancer. In addition, each awardee will yearly present a seminar at the monthly meeting of the Ovarian SPORE investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA083638-04
Application #
6667429
Study Section
Special Emphasis Panel (ZCA1)
Project Start
2002-09-27
Project End
2003-08-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
2002
Total Cost
$165,355
Indirect Cost
Name
Fox Chase Cancer Center
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19111
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 25:1384
Gabbasov, Rashid; Xiao, Fang; Howe, Caitlin G et al. (2018) NEDD9 promotes oncogenic signaling, a stem/mesenchymal gene signature, and aggressive ovarian cancer growth in mice. Oncogene 37:4854-4870
Chiang, Cheryl Lai-Lai; Kandalaft, Lana E (2018) In vivo cancer vaccination: Which dendritic cells to target and how? Cancer Treat Rev 71:88-101
Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15
Nacson, Joseph; Krais, John J; Bernhardy, Andrea J et al. (2018) BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance. Cell Rep 24:3513-3527.e7
Prudnikova, Tatiana Y; Chernoff, Jonathan (2017) The Group I Pak inhibitor Frax-1036 sensitizes 11q13-amplified ovarian cancer cells to the cytotoxic effects of Rottlerin. Small GTPases 8:193-198
Beck, Tim N; Smith, Chad H; Flieder, Douglas B et al. (2017) Head and neck squamous cell carcinoma: Ambiguous human papillomavirus status, elevated p16, and deleted retinoblastoma 1. Head Neck 39:E34-E39
Yang, Lu; Zhang, Youyou; Shan, Weiwei et al. (2017) Repression of BET activity sensitizes homologous recombination-proficient cancers to PARP inhibition. Sci Transl Med 9:
Skates, Steven J; Greene, Mark H; Buys, Saundra S et al. (2017) Early Detection of Ovarian Cancer using the Risk of Ovarian Cancer Algorithm with Frequent CA125 Testing in Women at Increased Familial Risk - Combined Results from Two Screening Trials. Clin Cancer Res 23:3628-3637
Zhang, Dongmei; Zhang, Gao; Hu, Xiaowen et al. (2017) Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer. Cancer Res 77:3745-3757

Showing the most recent 10 out of 323 publications